Evaluation of carbamazepine and carbamazepine-epoxide protein binding in patients undergoing epilepsy surgery

Epilepsia

Volumn 37, Issue 4, 1996, Pages 381-385

  Gidal, Barry E ^a   Spencer, Nancy W ^b   Maly, Melissa M ^b   Pitterle, Michael E ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Carbamazepine; Carbamazepine epoxide; Epilepsy surgery; Protein binding

Indexed keywords

ALBUMIN; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; FELBAMATE; GABAPENTIN; OROSOMUCOID; PHENOBARBITAL; PHENYTOIN; PRIMIDONE;

ADULT; ANTICONVULSANT THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; EPILEPSY; FEMALE; HUMAN; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; TEMPORAL LOBECTOMY;

ADULT; BLOOD PROTEINS; CARBAMAZEPINE; EPILEPSIES, PARTIAL; EPILEPSY, TEMPORAL LOBE; FEMALE; HUMANS; MALE; OROSOMUCOID; POSTOPERATIVE PERIOD; PROTEIN BINDING; SERUM ALBUMIN; TEMPORAL LOBE;

EID: 0029944827     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1996.tb00576.x     Document Type: Article

References (19)

1. Leppik IE. Intractable epilepsy in adults. Epilepsy Res 1992; suppl 5:7-11.
2. Cruz-Rodriguez RF, Graves NM, Leppik IE, Wilder R. Carbamazepine toxicity after surgery. Epilepsia 1989;30:640.
3. Hahn JF, Lüders H. Placement of surgical grid electrodes at the Cleveland Clinic. In: Engel J Jr, ed. Surgical treatment of the epilepsies. Raven Press, New York, 1987;621-7.
4. Cloyd J. Pharmacokinetic pitfalls of present antiepileptic medications. Epilepsia 1991;32(suppl 5):53-65.
5. Spencer SS, Packey DJ. Antiepileptic drug management before and after epilepsy surgery. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs, 4th ed. New York: Raven Press, 1995:189-200.
6. Levy RH, Wilensky AJ, Anderson GD. Carbamazepine, valproic acid, phenobarbital and ethosuximide. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics, 3rd ed. Vancouver, WA: Applied Therapeutics, 1992;25:1-29.
7. MacKichan JJ. Influence of protein binding and use of unbound drug concentrations. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics, 3rd. ed. Vancouver, WA: Applied Therapeutics, 1992;5:1-49.
8. Young AB, Ott LG, Beard D, Dempsey RJ, Tibbs PA, McClain CJ. The acute phase response in the brain injured patient. J Neurosurg 1988;69:375-80.
9. Elfstrom J. Drug pharmacokinetics in the postoperative period. Clin Pharmacokinet 1979;4:16.
10. Baruzzi A, Contin M, Perucca E, Albini F, Riva R. Altered serum protein binding of carbamazepine in disease states associated with an increased alpha-1 acid glycoprotein concentration. Eur J Clin Pharmacol 1986;31:85-9.
11. Contin M, Riva R, Albani F, Perucca E, Lamontanara G, Baruzzi A. Alpha-1 acid glycoprotein concentration and serum protein binding of carbamazepine and carbamazepine 10,11 epoxide in children with epilepsy. Eur J Clin Pharmacol 1985;29:211-4.
12. MacKichan JJ, Zola EM. Determinants of carbamazepine and carbamazepine 10,11 epoxide binding to serum protein, albumin and alpha-1 acid glycoprotein. Br J Clin Pharmacol 1984;18:487-93.
13. Kodama Y, Tsutsumi K, Kuranari M, Kodama H, Fujii I, Takeyama M. In vivo binding characteristics of carbamazepine and carbamazepine 10,11 epoxide to serum proteins in paediatric patients with epilepsy. Eur J Clin Pharmacol 1993;44:291-3
14. Chelberg RD, Gunawan S, Trieman DM. Simultaneous high-performance liquid chromatographic determination of carbamazepine and its principal metabolites in human plasma and urine. Ther Drug Monit 1988;110:188-93.
15. Levy RH, Friel PN, Johno I, et al. Filtration for free drug level monitoring: carbamazepine and valproic acid. Ther Drug Monit 1984,6:67-76.
16. Giardina E-G, Raby K, Freilich D, Vita J, Brem R, Louie M. Time course of alpha-1 acid glycoprotein and its relation to myocardial enzymes after acute myocardial infarction. Am J Cardiol 1985;56:262-5.
17. Agostoni A, Vergani C, Stabilini R, et al. Immunochemical quantification of acute phase reactive proteins in myocardial infarction. Am Heart J 1970;80:313-8.
18. Chen YL, Florentin I, Batt AM, Ferrari L, Giroud JP, Chauvelot-Moachon L. Effects of interleukin-6 on cytochrome p450-dependent mixed function oxidases in the rat. Biochem Pharmacol 1992;44:137-48.
19. Fukuda Y, Ishida N, Noguchi T, Kappas A, Sassa S. Interleukin-6 down regulates the expression of transcripts encoding cytochrome P450 IA1, IA2 and IIIA3 in human hepatoma cells. Biochem Biophys Res Commun 1992;184:960-5.